-
公开(公告)号：US20230210860A1
公开(公告)日：2023-07-06
申请号：US17818294
申请日：2022-08-08
发明人： Takeki UEHARA , Toru ISHIBASHI , Takao SHISHIDO , Keita FUKAO , Motoyasu OONISHI , Barry CLINCH , Jaspinder RANDHAWA
IPC分类号： A61K31/5383 , A61K31/215 , A61P31/16
CPC分类号： A61K31/5383 , A61K31/215 , A61P31/16
摘要： A method for treating an influenza virus infection is described. The disclosed method generally involves administering an effective amount of a compound (A), for example baloxavir marboxil, and a compound (B), for example a neuraminidase inhibor, to a subject that (1) has an influenza virus infection, (2) has been symptomatic of the influenza virus infection for no more than 96 hours, and (3) further has at least one severe influenza condition selected from the following: (a) being hospitalized due to severe influenza virus infection, (b) requiring an extension of hospitalization because of the influenza virus infection during the hospitalization, (c) having a National Early Warning Score 2 of four or more, (d) being on support for respiration, and (e) having at least one complication attributable to the influenza virus infection that necessitates hospitalization.
-
公开(公告)号：US20230122620A1
公开(公告)日：2023-04-20
申请号：US18079729
申请日：2022-12-12
发明人： Dainis Kaldre , Joerg Sedelmeier
IPC分类号： C07D239/70 , B01J31/12
摘要： Provided herein is a process for synthesis of intermediates for ipatasertib related to large scale manufacture of (R)-5-methyl-4-(piperazin-1-yl)-5,6-dihydro-7H-cyclopenta[d]pyrimidin-7-one.
-
公开(公告)号：US20230082465A1
公开(公告)日：2023-03-16
申请号：US17793483
申请日：2021-02-19
IPC分类号： C07K16/36
摘要： This application relates to anti-D-Dimer recombinant antibodies that specifically bind to fibrin and fibrinogen degradation products (FDP) such as D-Dimer, fragment DD and fragment D with high binding affinity and do not bind to fragment E and fibrinogen. The present invention also refers to methods and assays for detection of D-Dimer and FDP fragments in samples using said recombinant antibodies.
-
公开(公告)号：US11352438B2
公开(公告)日：2022-06-07
申请号：US16330269
申请日：2017-09-05
摘要： An objective of the present invention is to provide an effective pharmaceutical composition or a dosage regimen for preventing and/or treating bleeding, a disease accompanying bleeding, or a disease caused by bleeding. The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes (a) blood coagulation factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, bleeding, a disease accompanying bleeding, or a disease caused by bleeding can be prevented and/or treated more effectively.
-
![Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline Compounds for the Treatment of Autoimmune Disease](/abs-image/US/2021/12/02/US20210371432A1/abs.jpg.150x150.jpg)
5.发明申请公开(公告)号：US20210371432A1
公开(公告)日：2021-12-02
申请号：US16972556
申请日：2019-06-03
发明人： FABIAN DEY , HONG SHEN , HONGTAO XU , HONGYING YUN , GE ZOU , WEI ZHU
IPC分类号： C07D519/00 , C07D487/04
摘要： The present invention relates to compounds of formula (I), wherein R1 to R6, m and n are I a described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
-
公开(公告)号：US20210276999A1
公开(公告)日：2021-09-09
申请号：US17062853
申请日：2020-10-05
发明人： Hongyan QI , Soongyu CHOI , Amal DAKKA , Gary Mitchell KARP , Jana NARASIMHAN , Nikolai NARYSHKIN , Anthony A. TURPOFF , Marla L. WEETALL , Ellen WELCH , Matthew G. WOLL , Tianle YANG , Nanjing ZHANG , Xiaoyan ZHANG , Xin ZHAO , Luke GREEN , Emmanuel PINARD , Hasane RATNI
IPC分类号： C07D471/04 , A61K31/519 , C07D239/70 , C07D519/00 , C07D487/04
摘要： Provided herein are compounds of Formula (I): and forms thereof, including compositions thereof and uses therewith for treating spinal muscular atrophy.
-
公开(公告)号：US11077132B2
公开(公告)日：2021-08-03
申请号：US15549021
申请日：2016-02-04
发明人： Richard E. Olson , Angela M. Cacace , Peter Hagedorn , Anja Mølhart Høg , Marianne Lerbech Jensen , Niels Fisker Nielsen , Dong Li , Jeffrey M. Brown , Stephen E. Mercer
IPC分类号： A61K31/712 , C12N15/113 , A61P25/28
摘要： The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
-
公开(公告)号：US20210079103A1
公开(公告)日：2021-03-18
申请号：US16936457
申请日：2020-07-23
发明人： Jay Soto , Daniel Keith Ness , Martin Koller , Diane Mould , Frank Boess , Meret Martin-Facklam , Valerie Cosson , Hans Peter Grimm , Ronald Gieschke , Sara Belli , Silke Weber
摘要： The invention provides dosage regimes for treatment of synucleinopathies. In one regime, a subject receives 3000-5000 mg of an antibody intravenously every 3-5 weeks. In another regime, a subject receives 1300-1700 mg of an antibody intravenously every 3-5 weeks.
-
公开(公告)号：US20210003559A1
公开(公告)日：2021-01-07
申请号：US16912391
申请日：2020-06-25
发明人： Cristina Bertinetti-Lapatki , Lauriane Cabon , Adrian B. Roth , Annie Moisan , Nikolche Gjorevski , Jordan S. Kerns , Geraldine A. Hamilton , Catherine Karalis , Heather Grant , Riccardo Barrile , Debora Barreiros Petropolis , Chaitra Belgur
IPC分类号： G01N33/50
摘要： Disclosed herein is a method for assessing a compound interacting with a target on polarized epithelial cells. The method comprising the steps of providing an organ chip comprising a main channel and polarized epithelial cells, wherein the main channel is divided into an apical channel and a basal channel separated by the polarized epithelial cells, wherein the apical side of the polarized epithelial cells is directed towards the apical channel and the basolateral side of the polarized epithelial cells is directed towards the basal channel. Determining the localization and optionally the expression level of the target on the polarized epithelial cells. Administering the compound and optionally immune cells, preferably peripheral blood mononuclear cells (PBMC) to the basal channel, when the target is localized on the basolateral side of the epithelial cells or administering the compound and optionally immune cells, preferably peripheral blood mononuclear cells (PBMC) to the apical channel, when the target is localized on the apical side of the epithelial cells. Measuring a parameter of the administration of the compound and the peripheral blood mononuclear cells.
-
公开(公告)号：US10799523B2
公开(公告)日：2020-10-13
申请号：US15016169
申请日：2016-02-04
发明人： Richard E. Olson , Angela M. Cacace , Peter Hagedorn , Anja Mølhart Høg , Dong Li , Jeffrey M. Brown , Marianne Lerbech Jensen , Niels Fisker Nielsen , Stephen E. Mercer
IPC分类号： A61K31/712 , C12N15/113 , A61P25/28
摘要： The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
-
-
-
-
-
-
-
-
-
搜索结果
276 条记录 (耗时 0.036 秒)
